 "Serum Institute puts India trials of AstraZeneca's Covid-19 vaccine on hold")
MUMBAI (Reuters) - Serum Institute of India has put trials of AstraZeneca's COVID-19 vaccine candidate on hold until the British drugmaker restarts the trials, Serum said on Thursday.
"We are reviewing the situation and pausing India trials," Serum said in a brief statement.
AstraZeneca said on Tuesday it had paused trials of its experimental coronavirus vaccine because of an unexplained illness in a study participant, but its partner Serum had at the time said its trials in India were still ongoing.
(Reporting by Euan Rocha in Mumbai; Additional reporting by Sachin Ravikumar in Bengaluru; Editing by Shounak Dasgupta)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app